AzTrials
AzTrials

Yellow FeverPhase 4NCT01290055

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

A Phase 4 study testing Yellow fever vaccine and Deuterium (70% enriched 2H2O) labeled water in people with Yellow Fever, run by Sri Edupuganti at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The yellow fever vaccine is a live, attenuated virus that results in a robust immune response, especially in the T cell compartment. The researchers have been studying immune responses to live viral infections using the yellow fever vaccine as a model for a live viral infection. Read more about this study

Who is it for?
Ages 18 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Yellow Fever
What is being tested?
Yellow fever vaccine and Deuterium (70% enriched 2H2O) labeled water
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
27 participants
Where
1 siteUnited States
Study dates
15 Apr 2019to 25 Oct 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Able to understand and give informed consent
  • Age 18-45 years
  • Participant agrees not to take any live vaccines 30 days before or after (14 days for inactivated, including coronavirus disease 2019 (COVID-19) vaccination) yellow fever vaccination (not applicable to Group 3 and 4b participants)
  • Participant agrees to not receive any other vaccination during the 2H2O labeling period
  • Women of child bearing potential must agree to use effective birth control for the entire duration of the study. A negative urine pregnancy test must be documented prior to vaccination or 2H2O intake. Participants who have a history of surgical sterilization or post-menopausal status >1 year, are not required to have a pregnancy test.
  • Positive for the HLA-A2 allele (not applicable to Group 3 or 4 participants)

Who cannot join

  • Prior receipt of a yellow fever vaccine (not applicable for Group 2 participants)
  • Lived in a country/area which is endemic for yellow fever (not applicable to Group 2 participants)
  • Travel to country/area which is endemic for yellow fever. Subject to investigator discretion
  • History of previous West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection
  • Any history of allergy to eggs, chicken or gelatin or to any previous vaccine (not applicable to Group 2 (if received YFV-17D outside of study), 3 and 4b participants)
  • A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study.
Show all 16Show fewer
  • History of HIV infection
  • Active Hepatitis B or Hepatitis C infection
  • COVID-19 infection within 30 days prior to enrollment. Symptoms of COVID-19 must be completely resolved before enrollment.
  • History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications (ex, prednisone) for 2 weeks or more in the past 3 months.
  • History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial
  • Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of autoimmune disorder
  • History of neurological or neurodegenerative disorders (ex, Guillain-Barré, peripheral neuropathy, epilepsy, etc.). Subject to investigator assessment and discretion.
  • Receipt of a blood products or immune globulin product within 42 days of enrollment. Participants who received COVID monoclonal antibodies (mAbs) for treatment are not excluded.
  • Pregnant women and nursing mothers or women who are planning to become pregnant for the duration of the study.
  • Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The Hope Clinic of Emory Vaccine Center

    Decatur, Georgia, 30030

Other trials in United States

About this study

Official title: Yellow Fever Heavy Water: Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

The yellow fever vaccine is a live, attenuated virus that results in a robust immune response, especially in the T cell compartment. The researchers have been studying immune responses to live viral infections using the yellow fever vaccine as a model for a live viral infection. In this study, the researchers are interested in looking at the processing and lifespan of yellow fever specific CD8 T cell by measuring DNA replication and cell proliferation in humans using a naturally occurring stable isotope called deuterium.

Read the detailed description

Yellow fever is a viral disease caused by the yellow fever virus (YFV). It is transmitted to humans through the bite of an infected mosquito and can result in a life-threatening infection with hepatitis, renal failure and coagulation abnormalities, and in severe cases, death. Yellow fever can be prevented by vaccination with the yellow fever vaccine (YFV-17D). Currently, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend vaccination for persons ≥ 9 months of age who are traveling to or living in a yellow fever endemic area.

A very interesting, but unexplained aspect of flavivirus biology is how infection with different members of the same virus family can lead to such diverse types of host-virus interactions and variable disease outcomes. For example, YFV infection can be fatal, but if the infected host survives, long-term protective immunity is seen. Alternatively, dengue virus causes an acute infection with associated acute disease manifestations; however, even more severe disease outcomes are observed following secondary infection with a distinct serologic type of dengue virus. Understanding why the human immune system can successfully contain one flavivirus infection, but not another is both a fascinating scientific enigma in human immunology and a topic with substantial practical importance to public health. Given the great global public health threats posed by epidemic and emerging flavivirus infections, and the need to define the biological basis of successful induction and maintenance of protective immunity by vaccination, elucidation of the immunologic mechanisms underlying the generation and maintenance of protective immunity to YFV vaccine should be extremely useful. Furthermore, definition of the attributes of such a highly effective vaccine should help expedite the development and evaluation of new and/or improved vaccines to prevent important prevalent and emerging infectious diseases.

The goal of this study is to use the live attenuated yellow fever vaccine, YFV-17D (YF-VAX®, Sanofi Pasteur) as a safe and effective model to study a primary, acute viral infection in humans. Yellow fever virus vaccine is the viral infection model that the researchers have chosen for the following reasons:

  • The 17D attenuated yellow fever vaccine strain is one of the most efficacious vaccines available and has been in use since the 1930s.
  • YFV vaccination leads to limited infection without causing the disease.
  • Since most of the US population is not exposed to yellow fever virus, immunization of adult participants with the 17D vaccine strain allows for examination of the innate immunity and the naïve T and B cell response in humans during primary infection and the subsequent development of memory T cells after resolution of the primary infection.
  • The YFV-17D vaccine induces long-term immunity that lasts for decades. By studying how the human immune system responds to an effective vaccine such as the YFV-17D vaccine, the researchers hope to learn more about the normal functioning of the immune system so that it might be possible to design new, more effective vaccines to prevent important infectious diseases. Therefore, this vaccine can serve as an ideal model to help decipher the properties that make a vaccine effective.

YFV-17D is known to stimulate broad-spectrum immune responses, including cytotoxic T cells and Th1 and Th2 responses, as well as neutralizing antibody titers that can persist for up to 30 years, after a single vaccination. Despite the great success of this empiric vaccine, there has been relatively little understanding of the mechanisms by which YFV-17D induces such robust protective immune responses.

This study seeks to understand the lifespan and decay curve of effector CD8+ T cells and the rate of homeostatic turnover of memory CD8+ T cells after YFV-17D immunization using an innovative method developed by Dr. Marc Hellerstein's group (at the University of California, Berkeley) for measuring DNA replication and cell proliferation in humans using a naturally occurring stable isotope called deuterium (2H). This technique has been used to track the turnover of a number of human cell types in vivo. The researchers plan to use 2H labeling to track YFV specific CD8+ T cells in human vaccinees (HLA-A2 positive participants only). The availability of a T cell epitope (A2-NS4B^214), a major component of the human YFV specific CD8+ T cell response, allows for the longitudinal analysis of virus specific CD8+ T cells. The unique feature of this study is that it allows for tracking of differentiation of YFV specific CD8+ T cells in humans. Thus, the researchers can overcome the inherent limitations due to heterogeneity in cross sectional studies that involve bulk CD8+ T cells.

In addition, the researchers are proposing to study the life span and decay curve of monocytes after YFV vaccination. The mononuclear phagocytes comprise three types of cells: monocytes, macrophages, and dendritic cells (DCs). Mononuclear phagocytes play key functions in maintaining tissue homeostasis during steady state as well as orchestrating the genesis and resolution of the immune response. The kinetics underlying their generation, differentiation, and disappearance are critical to understanding both steady-state homeostasis and inflammatory responses. Using human in vivo deuterium labeling, it has been shown that classical monocytes emerge first from marrow, after a postmitotic interval of 1.6 days, and circulate for a day. Subsequent labeling of intermediate and nonclassical monocytes is consistent with a model of sequential transition. Intermediate and nonclassical monocytes have longer circulating lifespans (∼4 and ∼7 days, respectively). It is of great interest to determine the lifespan and decay of monocytes post-viral infection as modeled by administration of a live, attenuated yellow fever vaccination.

Deuterium labeled water (2H2O) or heavy water is chemically nearly the same as normal water but the hydrogen atoms are of the heavy isotope deuterium, in which the nucleus of the hydrogen atom contains a neutron in addition to the proton. When a person drinks 2H2O, it mixes with the body water. Proteins, DNA, RNA, lipids, and other biomolecules become "labeled"; the faster the biomolecules are being synthesized, the more they become labeled with deuterium. The deuterium labeled molecules can be measured by sampling blood and body fluids such as plasma, cerebrospinal fluid, sputum, urine, etc.

Participants will enroll into one of 8 study arms and will be given repeated small doses of 2H2O to drink and may receive the yellow fever vaccine, depending on the study arm they are in.

Conditions
Yellow Fever
Being tested
Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water
Keywords
Yellow Fever, Vaccine, Memory T Cells
Medical subject headings
Yellow Fever

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Yellow fever vaccineBiological

    Also called YF-VAX®

    The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.

  • Deuterium (70% enriched 2H2O) labeled waterOther

    Also called D20, deuterated water, 2H2O

    70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.

Study groups in NCT01290055
Study groupRoleWhat they receive
Group 1a - Drink deuterated water on days 0 - 14 post-vaccinationExperimentalParticipants testing positive for human leukocyte antigen-A2 (HLA-A2) will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 2 weeks, on Days 0 through 14 post-vaccination.
Receives: Biological: Yellow fever vaccine; Other: Deuterium (70% enriched 2H2O) labeled water
Group 1b - Drink deuterated water on days 14 - 28 post-vaccinationExperimentalParticipants testing positive for HLA-A2 will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1b will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 2 weeks, on Days 14 through 28 post-vaccination.
Receives: Biological: Yellow fever vaccine; Other: Deuterium (70% enriched 2H2O) labeled water
Group 1c - Drink deuterated water on days 0 - 28 post-vaccinationExperimentalParticipants testing positive for HLA-A2 will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1c will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 4 weeks, on Days 0 through 28 post-vaccination.
Receives: Biological: Yellow fever vaccine; Other: Deuterium (70% enriched 2H2O) labeled water
Group 2a - Drink deuterated water 2 months post-vaccinationExperimentalTo assess the homeostatic proliferation of Memory CD8 T cells, participants in group 2a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water 2 months post-vaccination.
Receives: Biological: Yellow fever vaccine; Other: Deuterium (70% enriched 2H2O) labeled water
Group 2b - Drink deuterated water 6 months post-vaccinationExperimentalTo assess the homeostatic proliferation of Memory CD8 T cells, participants in group 2b will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water 6 months post-vaccination.
Receives: Biological: Yellow fever vaccine; Other: Deuterium (70% enriched 2H2O) labeled water
Group 3 - Drink deuterated water for up to 8 weeks without vaccinationExperimentalTo assess homeostatic turnover of CD8+ T lymphocytes in general, unvaccinated participants will be asked to drink deuterium (70% enriched 2H2O) labeled water for up to 8 weeks.
Receives: Other: Deuterium (70% enriched 2H2O) labeled water
Group 4a - Drink deuterated water on days 0 - 7 post-vaccination, with fine needle aspirateExperimentalTo assess homeostatic turnover of monocytes participants in group 4a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water on Days 0 through 7 post-vaccination. Participants will undergo two fine needle aspirate (FNA) procedures to examine the immune response in the lymph nodes.
Receives: Biological: Yellow fever vaccine; Other: Deuterium (70% enriched 2H2O) labeled water
Group 4b - Drink deuterated water for 7 days without vaccinationExperimentalTo assess homeostatic turnover of monocytes participants in group 4b, unvaccinated participants will will be asked to drink deuterium (70% enriched 2H2O) labeled water for 7 days post enrollment.
Receives: Other: Deuterium (70% enriched 2H2O) labeled water

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lifespan of Effector CD8 T Cells

    The life span of effector CD8 T cells after immunization with 17D yellow fever vaccine is measured in days. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  2. Decay Curve of Effector CD8 T Cells

    The decay curve of effector CD8 T cells after immunization with 17D yellow fever vaccine is measured in days. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  3. Homeostatic Turnover of Memory CD8 T Cells

    The rate of homeostatic turnover of memory CD8 T cells after immunization with 17D yellow fever vaccine. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  4. Lifespan of Monocytes

    The life span of monocytes after immunization with 17D yellow fever vaccine is measured in days. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  5. Decay Curve of Monocytes

    The decay curve of monocytes after immunization with 17D yellow fever vaccine is measured in days. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

Secondary outcomes (8)
  1. Magnitude of T Cell Responses

    Standard immunological assays will be performed to evaluate the magnitude of T Cell response. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  2. Kinetics of T Cell Responses

    The kinetics of T Cell responses will be characterized with the different study arms. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  3. Magnitude of B Cell Responses

    Standard immunological assays will be performed to evaluate the magnitude of B Cell response. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  4. Kinetics of B Cell Responses

    The kinetics of B Cell responses will be characterized with the different study arms.. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  5. Turnover of Epstein-Barr Virus (EBV)-Specific CD8 T Cells

    The turnover of EBV cluster of differentiation 8 (CD8) T cells will be examined. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  6. Turnover of Cytomegalovirus (CMV)-Specific CD8 T Cells

    The turnover of CMV cluster of differentiation 8 (CD8) T cells will be examined. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  7. Magnitude of Monocytes

    Standard immunological assays will be performed to evaluate the magnitude of monocytes. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

  8. Kinetics of Monocytes

    The kinetics underlying the generation, differentiation, and disappearance of monocytes post-administration of the yellow fever vaccine is examined by the number of classical, intermediate, and nonclassical monocytes. Classical monocytes emerge first from marrow, after a postmitotic interval of 1.6 days, and circulate for a day. Intermediate and nonclassical monocytes have longer circulating lifespans of approximately 4 and 7 days, respectively. The schedule of follow up visits depends on the study arm that the participant is in.

    Measured: Up to Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2011 (estimated)
  2. Study start15 Apr 2019
  3. Primary completion25 Oct 2024
  4. Study completion25 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01290055
Sponsor's protocol ID
IRB00046406
Other IDs
U19AI057266
Status last verified
Apr 2025
First submitted
3 Feb 2011
Last updated
29 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Yellow fever vaccine and Deuterium (70% enriched 2H2O) labeled water in people with Yellow Fever, run by Sri Edupuganti at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lifespan of Effector CD8 T Cells (time frame: Up to Month 12). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in